Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10329391 | 0.82 | SIGMAR1 (0.33) | PARP15PARP10PARP2ACACB | |
| SCHEMBL16882662 | 0.81 | MAOA (0.34) | PARP15PARP10PARP2TDP1ACACB | |
| SCHEMBL10329400 | 0.81 | MAOA (0.34) | PARP15PARP10PARP2TDP1ACACB | |
| SCHEMBL10329392 | 0.80 | ALDH1A1 (0.53) | TDP1 | |
| SCHEMBL13651823 | 0.79 | MAPT (0.39) | — | |
| SCHEMBL13183274 | 0.78 | NQO1 (0.47) | TDP1ACACB | |
| SCHEMBL10329398 | 0.78 | TDP1 (0.31) | TDP1 | |
| SCHEMBL9291787 | 0.76 | HRH3 (0.54) | PARP15PARP10PARP2TDP1ACACB | |
| SCHEMBL9561962 | 0.76 | HRH3 (0.54) | PARP15PARP10PARP2TDP1ACACB | |
| SCHEMBL9291783 | 0.76 | HRH3 (0.54) | PARP15PARP10PARP2TDP1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | OXER1, NOX1, NOX4 | PARP15 1044/4885PARP10 3288/4885PARP2 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.